January 11, 2019

US top court rejects Amgen over cholesterol medication patent fight

Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

Read the source article at channelnewsasia.com



Additional Articles You May Like

Sign Up To Receive Our Free Newsletter